文献速递糖尿病肥胖与代谢综合征性腺与生殖内分泌

芳香化酶抑制剂治疗的绝经后乳腺癌患者胰岛素抵抗与脂肪增加

Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors.
PubMed 文献 · J Clin Endocrinol Metab · 2019-01-01

这项病例对照研究纳入20例接受芳香化酶抑制剂治疗的绝经后乳腺癌患者和20例年龄匹配对照,发现患者胰岛素敏感性指数更低、口服葡萄糖耐量试验后胰岛素峰值更高、体脂百分比更高、血浆瘦素浓度更高,提示芳香化酶抑制剂治疗与体脂增加和胰岛素抵抗相关。

要点

  • 芳香化酶抑制剂治疗的绝经后乳腺癌患者胰岛素敏感性显著低于对照。
  • 患者体脂百分比和血浆瘦素浓度均显著高于无乳腺癌病史对照。
  • 临床应关注此类患者代谢风险,但研究为小样本病例对照。

核心结论

  • 接受芳香化酶抑制剂治疗的绝经后乳腺癌患者体脂百分比更高且胰岛素抵抗更明显。

研究设计与样本

  • 病例对照研究,纳入20例接受芳香化酶抑制剂治疗的绝经后乳腺癌患者和20例年龄匹配对照。
  • 主要结局为75g口服葡萄糖耐量试验衍生的Matsuda胰岛素敏感性指数,体成分用双能X线吸收法评估。

主要发现

  • 芳香化酶抑制剂组胰岛素敏感性指数为5.15±0.45,显著低于对照组的6.80±0.64(P=0.041)。
  • 芳香化酶抑制剂组口服葡萄糖耐量试验后胰岛素峰值为693.4±78.6 pmol/L,显著高于对照组的527.6±85.5 pmol/L(P=0.035)。
  • 芳香化酶抑制剂组体脂百分比为38.4%±1.0%,显著高于对照组的34.6%±1.3%(P=0.026)。
  • 芳香化酶抑制剂组血浆瘦素浓度为23.5±2.8 ng/mL,显著高于对照组的15.5±2.3 ng/mL(P=0.035)。

临床怎么用

  • 对接受芳香化酶抑制剂治疗的绝经后乳腺癌患者,可关注体脂增加和胰岛素抵抗等代谢变化。

局限性

  • 研究为小样本病例对照设计,仅纳入20例患者和20例对照。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

CONTEXT: Aromatase deficiency causes obesity and insulin resistance in aromatase knockout mice and humans with rare mutations of the aromatase gene (CYP19). Aromatase inhibitors are a commonly prescribed therapy for postmenopausal breast cancer. OBJECTIVE: We hypothesized that aromatase inhibitors induce obesity and insulin resistance when used in treatment of breast cancer. DESIGN: Case-control study. SETTING: University teaching hospital. PARTICIPANTS: Patients with postmenopausal breast cancer (n = 20) treated with aromatase inhibitors and 20 age-matched control subjects. MAIN OUTCOME MEASURES: The primary outcome measure was insulin sensitivity index - Matsuda, derived from a 75-g oral glucose tolerance test. Body composition was assessed by dual energy x-ray absorptiometry and biopsy specimens of subcutaneous adipose tissue obtained for assessment of mRNA transcript levels. Data are reported as mean ± SEM (patients receiving inhibitors vs control group, respectively). RESULTS: Aromatase inhibitor therapy was associated with significantly lower insulin sensitivity (5.15 ± 0.45 vs 6.80 ± 0.64; P = 0.041), higher peak insulin concentration after oral glucose tolerance test (693.4 ± 78.6 vs 527.6 ± 85.5 pmol/L; P = 0.035), greater percentage of body fat (38.4% ± 1.0% vs 34.6% ± 1.3%; P = 0.026), and higher plasma leptin concentration (23.5 ± 2.8 vs 15.5 ± 2.3 ng/mL; P = 0.035). CONCLUSION: Women who received aromatase inhibitors for postmenopausal breast cancer had greater percentage body fat and insulin resistance compared with control subjects with no history of breast cancer.

来源:J Clin Endocrinol Metab,查看原文。版权归原作者所有。

引用

  1. Gibb FW, Dixon JM, Clarke C, et al. Higher Insulin Resistance and Adiposity in Postmenopausal Women With Breast Cancer Treated With Aromatase Inhibitors. J Clin Endocrinol Metab. 2019. PMID: 30920624. doi:10.1210/jc.2018-02339

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。